Kornimate/medical-research-clean huggingface dataset:
quantitative mri of bone marrow fat fraction in patients with trepanobiopsy

Conditions: Aplastic Anemia; Aplastic Anemia Idiopathic

Summary: the study is aimed to find correlation between the assessment of cellularity according to trepanobiopsy data and the results of measuring mri parameters.

the ratio of fat to water in the bone marrow depends on the cellularity of the bone marrow. in addition to the water/fat ratio in bone marrow there are also other parameters for quantitative mri assessment. these include the apparent diffusion coefficient (acd), the t1 relaxation time, mapping of the macromolecular proton fraction. the undoubted advantage of mri is its non-invasiveness and the ability to assess any localization of the bone marrow. mri may become a new non-invasive method for assessing the cellularity of the bone marrow in children with oncohematological diseases.

Eligibility criteria:
inclusion criteria: presence of indications for performing trepanobiopsy: 1. aplastic anemia 2. chronic myeloproliferative disease 3. reactive changes in hematopoiesis exclusion criteria: 1. refusal to sign an informed consent to participate in a clinical trial 2. presence of contraindications for mri examination 3. extremely serious condition of the patient at the time of inclusion in the study.

Keywords: quantitative mri trepanobiopsy aplastic anemia idiopathic children
core strengthening versus lower limb proprioceptive neuromuscular facilitation techniques in chronic stroke patients

Conditions: Stroke

Summary: stroke is a global healthcare issue that causes increased death rates. good trunk stability is essential for balance and extremity use during daily functional activities and higher-level tasks. the anticipatory activity of trunk muscles is impaired in stroke patients. the trunk is the central column of the body; therefore, proximal trunk control is a prerequisite for distal limb movement control, balance, and functional activities. the purpose of the study is to highlight the most appropriate rehabilitation technique for trunk stability.

a randomized clinical trial will be performed in which 42 patients with strokes will be included. the data will be collected from riphah rehabilitation center lahore and ittefaq hospital lahore. consecutive sampling technique will be used to collect data. the duration of the study will be 10 months. trunk impairment scale and berg balance scale will be used as the data collection tool. data collection will be started after taking informed consent from all the patients. patients will be allocated to intervention groups by randomization. the patients in group a will be given core strengthening exercise for 4 weeks. the patient in group b will be given pnf exercise for the treatment of trunk for 4 weeks. after data collection analysis of pre and post values will be done by using spss version 25.

Eligibility criteria:
inclusion criteria: * chronic stroke patients (6 months to 2 years). * participants with first ever ischemic stroke of right or left half of the body. * participants should be able to walk without support for 10 m. * mmse score is ≥ 24. exclusion criteria: * participants with recurrent stroke; brainstem or cerebellar stroke or hemorrhagic stroke will be excluded. * patients with speech problem after stroke * patients with other neurological disorders including: parkinson's disease, multiple sclerosis, epilepsy, etc.

Keywords: proprioceptive neuromuscular facilitation; stroke
weighted blankets for iud insertion

Conditions: Intra-uterine Device Placement

Summary: when having an intrauterine device placed in an outpatient clinic, patients frequently feel anxiety related to the procedure. this study is designed to determine if the use of a small, weighted blanket, placed over the patient's chest and shoulders, would help decrease that anxiety, as well as pain related to the procedure.

patients scheduled for an iud placement in this specific outpatient clinic will be approached by the study nurse to gauge interest in participating. consented patients will be randomized to either receive a weighted blanket or a non-weighted blanket. patients will rate their anxiety on a 100 mm visual-analog scale and pain on a 0-10 verbal scale.

Eligibility criteria:
inclusion criteria: * scheduled for iud placement * age 18 years or older * able to read and understand english and use a pen exclusion criteria: * inability to consent * inability to remove weighted blanket

Keywords: weighted blanket gynecological procedure iud anxiety
exploring the genetics of neuropathic pain

Conditions: Neuropathic Pain; Genetic Predisposition; Polyneuropathies

Summary: in the present study the investigators will search for new genetic variants relevant for the development of neuropathic pain.

neuropathic pain is defined as "pain caused by a lesion or disease of the somatosensory nervous system". neuropathic pain is a huge health problem worldwide, with an estimated prevalence of 7-8 % in the general population. in the present study the investigators will search for new genetic variants relevant for the development of this type of pain. peripheral nerve lesions only progress to neuropathic pain in some patients, yet is not completely understood why or how. genetic studies of patients with rare neuropathic disorders have been important for elucidating novel molecular mechanisms of neuropathic pain, and new drugs for neuropathic pain are now being developed based on these findings. by using genetic association studies, one may identify new genetic variants which may help to identify key molecular mechanisms for a larger group of patients with neuropathic pain. this project will use existing population-based cohorts, as well as establish a specific registry and biobank for patients with neuropathy in order to address these specific needs. this will allow the investigators to identify a large number of individuals with probable neuropathic pain and individuals with pain-free peripheral neuropathy (disease controls). international collaboration will contribute to study a large group of patients, which will be important in order to reach the project's goals. the results from the project are expected to increase current knowledge on the mechanisms of neuropathic pain, opening up new opportunities for innovative and improved treatments. dissemination of results will be organized in close collaboration with patient representatives, and will be done regularly throughout the course of the project. the will focus both on internal dissemination to the participating hospitals, and external dissemination through participation in conferences, submissions to scientific journals and by publishing patient-friendly information booklets and proactively informing media outlets and patient organizations.

Eligibility criteria:
inclusion criteria: 1. the patient is between 18 and 70 years old. 2. the patient has consented. 3. the patient is referred for evaluation of possible distal symmetric polyneuropathy (dspn). 4. the patient has filled out the questionnaires. exclusion criteria: 1. the patient is too sick to participate (eg. bedridden, fever). 2. the patient is unable to consent (eg. dementia, speech problems, psychiatric disorder). 3. inflammatory acute polyneuropathy.

Keywords: reliability validity
semaglutide in cfrd

Conditions: Cystic Fibrosis; Cystic Fibrosis-related Diabetes

Summary: this open label, single arm pilot study, will examine the safety and tolerability of glp-1ra semaglutide as an add-on therapy to insulin for overweight/obese adult patients with cystic fibrosis related diabetes (cfrd).

the overall goal of this proposal is to collect pilot data for safety and feasibility metrics to support a future larger randomized controlled trial. in this study, we will examine the safety and tolerability of glp-1ra semaglutide as an add-on therapy to insulin for overweight/obese adult patients with cfrd. we hypothesize that weekly administration of the long-acting glp-1ra semaglutide to overweight/obese cfrd patients will be safe and well tolerated. specific aim 1: collect pilot data on the safety and feasibility of weekly semaglutide therapy in overweight and obese patients with cfrd to support a future larger randomized controlled trial. hypothesis 1: weekly therapy with glp-1ra semaglutide will be safe and well tolerated in overweight/obese adults with cfrd. specific aim 2: collect preliminary data to examine the impact of semaglutide therapy on insulin secretion, glucagon and glucose levels as measured by oral glucose tolerance test (ogtt), and on glycemic outcomes as measured by continuous glucose monitoring (cgm) and hba1c. hypothesis 2a: treatment with semaglutide will lower glucose levels, and increase insulin and c-peptide area under the curve (auc) during the ogtt as compared to baseline. hypothesis 2b: treatment with semaglutide will improve glycemic control as indicated by time in range on cgm and hba1c

Eligibility criteria:
inclusion criteria: * adult subjects 18 years or older with cfrd and on insulin treatment * bmi \>26 kg/m2 * diagnosis of pancreatic insufficiency (based on treatment with pancreatic enzyme replacement therapy) * a participant who is capable of becoming pregnant must agree to take precautions that are effective in preventing pregnancy throughout this study. these methods could include one of the following 1. complete abstinence from sexual intercourse; 2. oral, injectable, or implanted hormonal contraceptives 3. intrauterine device 4. tubal ligation exclusion criteria: * personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2 (men2) * acute pulmonary exacerbation requiring iv antibiotics or systemic glucocorticoids within 4 weeks prior to baseline study procedures * gastrointestinal(gi) symptom exacerbation defined by current nausea/vomiting or diarrhea at the baseline assessment * history of chronic gi problems requiring hospitalization in the 1 year prior to baseline * history of clinically symptomatic pancreatitis * history of clinically significant gastroparesis * history of eating disorders * less than 24 weeks since start of a new cftr corrector/modulator therapy * pregnancy or lactation * severe cf liver disease * chronic kidney disease * history of suicide attempts or active suicidal ideation * non-english speakers and those unable to read in english

Keywords: cfrd
pharmacist-led therapeutic nutritional intervention in type 2 diabetes

Conditions: Diet Modification

Summary: type 2 diabetes represents a significant burden to both the individual and our healthcare system. individuals with type 2 diabetes are typically prescribed one or more glucose-lowering medications, many of which have undesirable side effects (e.g., nausea, risk of cardiovascular complications, weight gain) and cost our healthcare system a lot of money. an alternative strategy to lower blood glucose is to consume a low-carbohydrate diet. however, adjusting medications after choosing to follow a low-carbohydrate diet can be difficult. delivering a low-carbohydrate diet through pharmacists could circumvent this difficulty in medications adjustment because pharmacists are trained to adjust medications. in this study the investigators will determine whether type 2 diabetes patients can reduce medications and improve blood glucose by following a low-carbohydrate, low-calorie diet under the direction of a pharmacist.


Eligibility criteria:
inclusion criteria: between the ages of 30 and 75, have type 2 diabetes mellitus diagnosed by a physician, are taking one or more glucose-lowering medications, have a bmi ≥30, have no contraindications to following low-carbohydrate, energy-restricted, high-protein diet, and can read and speak english. exclusion criteria: exlcusion criteria are: 1. recent (within the last 2 years) diagnosis of coronary heart disease, stroke, or a heart attack. 2. unstable cardiovascular disorder. 3. history of liver disease. 4. history of kidney disease or impaired renal function. 5. previously undergone bariatric surgery. 6. multiple sclerosis or other diagnosed neurological disease. 7. currently pregnant or lactating, or planning on becoming pregnant in the next 12 months. 8. any form of cancer within the last 5 years. 9. body mass index (bmi) of \<30. 10. dietary restrictions that do not allow you to follow a low-carbohydrate, energy-restricted, high-protein diet (e.g., vegan, food allergies). 11. any sensitivities to the ingredients in the pre-packaged foods

Keywords: low-carbohydrate low calorie energy restricted
efficacy and tolerability of blephademodex wipes

Conditions: Demodex Blepharitis

Summary: primary objective - to evaluate efficacy of blephademodex eyelid hygiene wipe treatment with a subsequent maintenance period with blephaclean lid cleansing wipes in demodex blepharitis, as assessed by the change in ocular symptoms by a global discomfort scale (gds). secondary objectives * to evaluate the efficacy of blephademodex eyelid hygiene wipe treatment in demodex blepharitis as assessed by the change alone and in combination with a subsequent maintenance period of treatment with blephaclean eyelid cleansing wipes ocular symptoms by: adapted toss; sande; specific blepharitis symptoms; demodex count; ocular surface redness (efron scale); lid margin redness/swelling (efron / custom scale); dandruff coverage at bases of eyelashes; ocular surface staining (oxford scale; corneal only) * to evaluate subject and physician satisfaction with blephademodex eyelid hygiene wipes * to evaluate ease of use for blephademodex eyelid hygiene wipes * adverse events are documented and analyzed.


Eligibility criteria:
inclusion criteria: * patient \> 18 years old, all genders * able to read, to write and to fully understand german language * good general health as determined by the investigator by medical history and physical appearance * provision of written informed consent prior to inclusion * moderate to severe blepharitis - grade ≥ 2 (efron scale) * global discomfort score (gds) ≥ 4 * proof of demodex infestation by at least one of the following:demodex visible after lash manipulation;cylindrical dandruff along the lash line; lid margin itching; madarosis exclusion criteria: * history of ocular trauma, ocular infection or intra-ocular inflammation within the 3 months before screening visit * history of ocular refractive surgery and any other ocular surgeries within 3 months before screening visit * history of ocular allergy or ocular herpes within the 3 months before screening visit * history of inflammatory corneal ulcer within the 6 months before screening visit * sjogren syndrome or any other rheumatologic disease related dry eye * concurrent treatment with other eye drops (anti-infectives, steroids, prostaglandins (but artificial tears are ok). * specific exclusion criteria for women:patient who verbally confirms pregnancy or lactation; childbearing potential woman who is not using a reliable method of contraception (oral contraceptive, intra-uterine device, subcutaneous contraceptive implant, vaginal ring, patch or condom) and is not surgically sterilised
a phase 2a study to evaluate als-008176 in the virus challenge model

Conditions: Respiratory Syncytial Virus Infections

Summary: this study is designed to compare the antiviral effect of als-008176 compared to a placebo control in the respiratory syncytial virus challenge model.


Eligibility criteria:
inclusion criteria: * age 18 to 45 years, inclusive. * in good health with no history of major medical conditions * a total body weight ≥ 50 kg and a body mass index (bmi) of \> 18kg/m2. exclusion criteria: * acute or chronic medical illness * positive for human immunodeficiency virus, hepatitis b or c * nose or nasopharynx abnormalities * abnormal lung function
sced - wisdom enhancement for post-stroke depression

Conditions: Post-stroke Depression

Summary: one-third of stroke survivors experience post-stroke depression, but there are currently no official guidelines for supporting them. researchers aim to investigate whether the wisdom enhancement timeline technique can reduce depression in stroke survivors. the investigators also want to understand how this technique positively impacts mood, identity, self-esteem, and wisdom. the study will involve nine stroke survivors from the national health service (nhs) to gain insights into effective ways to support those with post-stroke depression.

one-third of stroke survivors have post-stroke depression. finding ways to help them feel more positive after such a challenging event can be tricky. right now, there are no official guidelines on the best way to support post-stroke depression, and research into this is still growing. that is why the investigators want to see if the wisdom enhancement timeline can improve the mood and overall well-being of people who have had a stroke. in this study, the investigators have two goals. first, the investigators want to see if the wisdom enhancement timeline technique can reduce depression in stroke survivors. second, the investigators aim to discover how this technique brings positive mood changes. the main question the investigators want to answer 1. does enhancing wisdom through the timeline technique improve psychological outcomes (mood, identity, self-esteem) in post-stroke depressed individuals? 2. in post-stroke depressed individuals, is the improvement in wisdom the first indicator of subsequent improvements in identity, self-esteem, and mood? it is hypothesised that wisdom will improve first following the session where wisdom is applied. this will then be followed by either identity or self-esteem, with mood improving last. to carry out this study, the investigators will work with three stroke survivors receiving care from the national health service (nhs). by focusing on this smaller group, the investigators hope to gain insights into the effectiveness of the technique in reducing depression and enhancing the lives of stroke survivors. this study is essential as it could help the investigators understand the best way to support those with post-stroke depression.

Eligibility criteria:
inclusion criteria: * had a stroke. * those who self-report as having difficulties with depression to a clinician. * have sufficient cognitive and communication abilities for informed consent and active engagement exclusion criteria: * under the age of 18. because this is the age when they are treated as an adult by uk law. * severe cognitive impairments or mental health difficulties that would hinder task engagement or provide informed consent. * medical instability jeopardising consistent participation or well-being. * significant risk concerns regarding safety to themselves or others. * substance use/dependency impacting adherence. * prescribed psychotropic medication less than 3 months ago. * currently involved in research.

Keywords: wisdom cbt cognitive behavioural therapy stroke depression
efficacy of extracorporeal biofeedback device for post-prostatectomy incontinence

Conditions: Prostate Neoplasm; Prostatectomy; Surgical Procedures, Robotic; Urinary Incontinence; Biofeedback; Pelvic Floor; Exercise

Summary: to evaluate the efficacy of postoperative pelvic floor muscle training using personalized extracorporeal biofeedback device among patients with post-prostatectomy incontinence

* post prostatectomy urinary incontinence (ppi) was common complication after radical prostatectomy among prostate cancer patients. * the prevalence of post-prostatectomy urinary incontinence was reported at 87%. * the pelvic floor muscle therapy (pfmt) using kegel exercise was first methods to prevent ppi after prostatectomy. * however, there was no standardized protocol of the pfmt and it was necessary of biofeedback to pfmt. * therefore, we hypothesis the efficacy of personalized device of pfmt with biofeedback among patients who underwent radical prostatectomy * in this study, we evaluate the efficacy of postoperative pelvic floor muscle training using personalized extracorporeal biofeedback device among patients with post-prostatectomy incontinence.

Eligibility criteria:
inclusion criteria: * prostate cancer patients who underwent robotic radical prostatectomy * neurovascular saving at least one side * bladder neck reconstruction at prostatectomy * posterior reconstruction at prostatectomy * patients who have post-prostatectomy incontinence after foley catheter removal exclusion criteria: * patients who have not post-prostatectomy incontinence after foley catheter removal * neurological deficits * anatomic deformities of pelvic bone * pelvic irradiation history * history of other major urological procedures * complications influencing urinary incontinence

Keywords: prostate cancer robot-assisted laparoscopic surgery radical prostatectomy post-prostatectomy incontinence pelvic floor muscle exercise extracorporeal biofeedback device
a study of novel anti-cancer agents in patients with previously untreated nsclc

Conditions: Metastatic Non-Small Cell Lung Cancer (NSCLC)

Summary: this study is designed to determine the efficacy and safety of durvalumab and/or novel oncology therapies, with or without chemotherapy, for first-line stage iv non-small cell lung cancer (nsclc)

this is a phase ib, open-label, multi-center study to determine the efficacy and safety of durvalumab and/or novel oncology therapies, with or without chemotherapy, for first-line stage iv non-small cell lung cancer (nsclc).

Eligibility criteria:
inclusion criteria: * histologically or cytologically documented stage iv nsclc not amenable to curative surgery or radiation * no prior chemotherapy or any other systemic therapy for metastatic nsclc * prior platinum-containing adjuvant, neoadjuvant, or definitive chemoradiation for advanced disease are eligible, if progression has occurred \>12 months from end of last therapy * known tumor pd-l1 status * tumors that lack activating egfr mutations and alk fusions or documented local test result for any other known genomic alteration for which a targeted therapy is approved in first line per local standard of care * who/ecog status at 0 or 1 at enrollment * life expectancy of at least 12 weeks * troponin i or t ≤ uln (per institutional guidelines) exclusion criteria: * active or prior documented autoimmune or inflammatory disorders * history of active primary immunodeficiency * any prior chemotherapy or any other systemic therapy for metastatic nsclc * untreated cns metastases

Keywords: first-line stage iv metastatic non-small cell lung cancer stage iv metastatic non-small cell lung cancer metastatic non-small cell lung cancer non-small cell lung cancer non-small cell lung non-small cell nsclc non-small cell lung carcinoma